Prostate Cancer - Results from #800

Evaluation of Treatment Outcomes of Prostate Cancer Patients With Lymph Node Metastasis Treated With Definitive Radiotherapy: Comparative Analysis of PSMA PET/CT and Conventional Imaging. June 10, 2024

Prostate Cancer Recurrence: Examining the Role of Salvage Radiotherapy Field and Risk Factors for Regional Disease Recurrence Captured on 18F-DCFPyL PET/CT. June 10, 2024

A Prospective Randomized Multicenter Study on the Impact of [18F]F-Choline PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk Prostate Cancer. June 10, 2024

PET radiotracers for whole-body in vivo molecular imaging of prostatic neuroendocrine malignancies. June 10, 2024

Urinary extracellular vesicle-derived miR-126-3p predicts lymph node invasion in patients with high-risk prostate cancer. June 7, 2024

The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers. June 7, 2024

Receipt of prostate-specific antigen test in Medicaid beneficiaries with and without HIV in 2001-2015 in 14 states. June 7, 2024

Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis. June 7, 2024

Natural language processing pipeline to extract prostate cancer-related information from clinical notes. June 7, 2024

Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. June 6, 2024

Risk calculators for the detection of prostate cancer: a systematic review. June 6, 2024

Access to Prostate-Specific Antigen Testing and Mortality Among Men With Prostate Cancer. June 6, 2024

RNASEH2B loss and PARP inhibition in advanced prostate cancer. June 6, 2024

Transperineal 3-Core Magnetic Resonance Imaging Ultrasound Fusion Targeted Plus Laterally 6-Core Systematic Biopsy in Prostate Cancer Diagnosis. June 6, 2024

Prostate-specific membrane antigen-PET/CT may result in stage migration in prostate cancer: performances, quantitative analysis, and potential criticism in the clinical practice. June 6, 2024

PARP inhibitors in prostate cancers, is it time for combinations? June 5, 2024

Obesogenic High-Fat Diet and MYC Cooperate to Promote Lactate Accumulation and Tumor Microenvironment Remodeling in Prostate Cancer. June 5, 2024

Circulating free insulin-like growth factor-I and prostate cancer: a case-control study nested in the European prospective investigation into cancer and nutrition. June 5, 2024

Lifetime Health and Economic Outcomes of Biparametric Magnetic Resonance Imaging as First-Line Screening for Prostate Cancer : A Decision Model Analysis. June 5, 2024

Multimodal, PSMA-Targeted, PAMAM Dendrimer-Drug Conjugates for Treatment of Prostate Cancer: Preclinical Evaluation. June 5, 2024

Page 41 of 1437